Media about us

• Syndax shares soar as lead drug clears a mid-stage cancer drug study hurdle

  17 May 2017 John Carroll / Endpoints News

  Briggs Morrison has good reason today to be glad he left the Big Pharma R&D world behind at AstraZeneca and switched to biotech. The CEO of Waltham, MA-based Syndax reported that the company’s lead drug in combination with Merck’s Keytruda cleared its first big hurdle in Phase II and will now transition into the second phase of the study.

• Epic Sciences nets $40M for cancer liquid biopsy

  02 May 2017 Amirah Al Idrus / FierceBiotech

  

  Epic Sciences raised $40 million in a Series D round, which it will use to ramp up clinical studies of its liquid biopsy tests that identify cancer patients who will benefit from specific treatments.

• Biopharma just can’t get enough of Epic Sciences

  02 May 2017 Juliet Preston / MedCityNews

  

  Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round, a whopping 42 industry partnerships and over 200 clinical trials in the works, all built around its novel liquid biopsy platform. For a team of just 70, the San Diego, California startup is doing pretty well.

• With $40M in New Cash, Epic Sciences Advances Diagnostic for Late-Stage Prostate Cancer

  02 May 2017 Bruce V. Bigelow / Xconomy

  

  When San Diego’s Epic Sciences raised $30 million almost three years ago, CEO Murali Prahalad told me he saw a big opportunity to use the company’s technology as a diagnostic test to assess how well a cancer patient is responding to specific anti-cancer drug regimens.

• Corneal inlays need your boost to hit their stride

  10 April 2017 John A. Hovanesian, MD, FACS / Healio

  

  Recently, ReVision Optics announced the implantation of the 1,000th Raindrop corneal inlay in the United States since its approval last August. The AcuFocus Kamra corneal inlay, which was approved earlier, has now reached nearly 4,000 U.S. implants, according to a source at the company.

• New help for that bane of middle-age: blurry close-up vision

  07 March 2017 Lauran Neergaad, AP Medical Writer / Associated Press

  

  Squinting while texting? Always losing your reading glasses? An eye implant that takes about 10 minutes to put in place is the newest in a list of surgical repairs for the blurry close-up vision that is a bane of middle age. But who's really a good candidate to toss their specs?

• Atlas to invest in extra capacity at STI test manufacturing partner Bespak

  16 February 2017 Dani Bancroft / InPharma Technologist.com

  

  Atlas Genetics has said it will expand manufacturing capacity for cartridgebased STI tests at a UK facility owned by drug delivery technology firm Bespak Europe ltd.

• Liquid biopsies: The next frontier in cancer?

  15 February 2017 Ned Pagliarulo / BioPharmaDive

  

  As immuno-oncology dazzles and pharma companies race to develop new cancer medicines, a similar boom is underway to speed up and improve the detection of cancers.

• Top 5 Vendors in the Pharmerging Market from 2017 to 2021: Technavio

  01 February 2017 Yahoo Finance

  

  The pharmaceutical industry worldwide witnesses a dramatic regional shift to the pharmerging market, owing to the opportunities available. Considering the on-going trend of shift in global medicine dosage consumption to developing countries, about 55-60% of the global consumption should come from pharmerging markets by 2021. This will eventually lead to an incremental growth of around 25% from 2016 level.

• Struggling Marinus gets a bump out of a positive PhII snapshot

  24 January 2017 Arsalan Arif / Endpoints News

  

  A lit­tle more than six months since its stock price was crushed by a failed late-stage pro­gram for its lead­ing — and only — drug, tiny biotech mi­cro­cap Mar­i­nus $MRNS saw its shares shoot up this morn­ing after it of­fered a pos­i­tive Phase II snap­shot on a hand­ful of pa­tients who suf­fer from a rare ge­netic ail­ment.